Abstract
Metrifonate is a long-acting irreversible cholinesterase inhibitor, originally used to treat schistosomiasis. Its potential to enhance central nervous system cholinergic neurotransmission led to clinical trials for the treatment of people with Alzheimer's disease (AD). Although low incidence of serious side effects occurred during short-term use as an antihelmintic, in studies of the treatment of AD extending over 6 months, 20 patients experienced respiratory paralysis and problems with neuromuscular transmission. These findings have led to a halt to trials of metrifonate for AD and Bayer, the pharmaceutical company, has withdrawn its FDA application. 1) To establish the efficacy of metrifonate for patients with Alzheimer's disease, in terms of cognition, global impression, functional activity, non cognitive symptoms, rate of institutionalization and mortality.2) Assess the safety and tolerability of metrifonate. The Cochrane Dementia and Cognitive Improvement Group's Specialized Register was searched on 5 December 2005 using the term metrifonat*. This Register is regularly updated with records from all major health care databases (MEDLINE, EMBASE, CINAHL, PsycINFO) and many trials databases. One of the authors (LS), as member ...Continue Reading
References
Oct 13, 1978·Archives of Toxicology·B HolmstedtA Sundwall
Oct 13, 1978·Archives of Toxicology·I NordgrenM Sandoz
May 1, 1992·Neurochemical Research·N OganeE Messamore
Jun 1, 1987·Neuropharmacology·M Hallak, E Giacobini
Jul 1, 1965·Toxicology and Applied Pharmacology·M ShermanM T Chang
Jul 30, 1982·Science·R T BartusA S Lippa
Mar 7, 1995·Neuroreport·F MoriE Giacobini
May 1, 1996·Journal of Clinical Pathology·G P SpickettJ Shrimankar
Jan 1, 1996·Alzheimer Disease and Associated Disorders·R E BeckerS Vicari
May 1, 1997·European Journal of Pharmacology·C ScaliG Pepeu
Apr 16, 1998·Alzheimer Disease and Associated Disorders·R E BeckerS Vicari
Apr 29, 1998·Journal of Clinical Pharmacology·L C PettigrewB Gulanski
May 22, 1998·Neurology·J L CummingsB Gulanski
May 22, 1998·Neurology·J C MorrisB Gulanski
Aug 26, 1998·Dementia and Geriatric Cognitive Disorders·I G McKeith
Aug 26, 1998·Dementia and Geriatric Cognitive Disorders·D Kaufer
Sep 3, 1998·European Journal of Pharmacology·M G GiovanniniG Pepeu
Mar 25, 1999·Clinical Therapeutics·M W JannB Gulanski
Jun 11, 1999·The Journal of Clinical Psychiatry·M A RaskindB I Gulanski
Nov 11, 1999·International Journal of Geriatric Psychiatry·B DuboisD Meulien
Mar 16, 2000·Alzheimer Disease and Associated Disorders·J P BlassB Gulanski
Mar 25, 2000·Journal of the American Geriatrics Society·R ShikiarB Dubois
Jun 27, 2000·Dementia and Geriatric Cognitive Disorders·M R Farlow, P A Cyrus
Dec 6, 2005·Alzheimer Disease and Associated Disorders·Lon S Schneider
Apr 21, 2006·The Cochrane Database of Systematic Reviews·J M López-Arrieta, L Schneider
Citations
Nov 9, 2010·International Journal for Parasitology·Maha M EissaNahed M Baddour
Nov 2, 2016·Molecular BioSystems·Yunqin ZhangZhili Zuo
Apr 22, 2009·Toxicology and Applied Pharmacology·Cristina OlmosFloria Pancetti
May 1, 2009·Therapeutic Advances in Neurological Disorders·Krista L LanctôtNathan Herrmann
Apr 21, 2006·The Cochrane Database of Systematic Reviews·J M López-Arrieta, L Schneider
Apr 12, 2007·Expert Review of Neurotherapeutics·Kevin R Scott, Anna M Barrett
Jul 1, 2009·Der Nervenarzt·H Förstl
Jun 4, 2014·International Journal of Molecular Sciences·Miroslav Pohanka
Apr 29, 2016·BMJ Open·Kate LaverMaria Crotty
May 18, 2020·International Journal of Molecular Sciences·Donald E Moss
Feb 10, 2011·Neurochemical Research·Wontae KimYoung Ho Koh
Jun 6, 2009·Parasitology·A Danso-AppiahJ Utzinger
Aug 20, 2015·The Journal of Parasitology·Flaviano Benavides-GonzálezIsidro Otoniel Montelongo-Alfaro
Jan 4, 2019·Bioorganic Chemistry·Prabhash Nath TripathiSushant K Shrivastava
Aug 19, 2007·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Betul Karademir CatalgolBuket Alpertunga